ArticleImmunology letters2012
Soluble B7-H1: differences in production between dendritic cells and T cells.
Article in Immunology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.Frontiers in immunology · 2023Pooled it
- Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Nature communications · 2024Trial
- Trial
- Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.Respiratory research · 2018Trial
- Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.International journal of nanomedicine · 2026Article
- Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs).Cancer immunology, immunotherapy : CII · 2025Article
- Soluble PD-L1: From Immune Evasion to Cancer Therapy.Life (Basel, Switzerland) · 2025Review
- Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever.PLoS pathogens · 2025Article
- Article
- Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer.Advances in biomarker sciences and technology · 2025Article
- Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma.Frontiers in oncology · 2025Article
- Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.Cancer immunology, immunotherapy : CII · 2024Article
- Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.Journal of experimental & clinical cancer research : CR · 2024Review
- Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies.Experimental & molecular medicine · 2024Review
- Exploring the dynamics of Programmed Death-Ligand 1 in canine lymphoma: unraveling mRNA amount, surface membrane expression and plasmatic levels.Frontiers in veterinary science · 2024Article
- PD-1 immunology in the kidneys: a growing relationship.Frontiers in immunology · 2024Review
- Prognostic significance of soluble PD-L1 in prostate cancer.Frontiers in immunology · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.